Re-Vana Therapeutics

Private

BelfastHealthcare & Life Scienceshttps://www.revanatx.com/

Last Round

Series A

Nov 30, 2022

Total Funding Raised

$17.46M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Re-Vana Therapeutics is a biotechnology company developing a sustained-release drug delivery platform for ophthalmic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Advanced Materials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

long-acting drug deliveryophthalmic drug deliverydrug delivery platformbiodegradable implantbiopharma licensingsustained release biologicsdrug-eluting implantocular implantpharma partneringinjectable gelspecialty pharmawet AMDdiabetic retinopathyglaucoma treatmentphoto-crosslinked polymerintravitreal injection

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Re-Vana Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Re-Vana Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Re-Vana Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Nov 30, 2022
Grant	May 1, 2022
Pre Seed	Jun 2, 2020
Grant	Aug 5, 2019
Seed	Nov 27, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Michael J. O'Rourke

CEO

Executive Team

Re-Vana Therapeutics Investors

Notable investors and investment history

Re-Vana Therapeutics investors
Investor	Rounds
QUBIS	Seed, Pre Seed, Series A
Invest Northern Ireland	Seed
Innovate UK	Grant
Clarendon Fund Managers	Seed, Pre Seed, Series A
Techstart Ventures	Seed, Pre Seed, Series A
Visionary Ventures	Pre Seed, Series A
InFocus Capital Partners	Pre Seed, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 20, 2026
Monthly visitors increased 69% MoM.
Nov 8, 2025
Monthly visitors increased by 87% MoM.

View all signals

Re-Vana Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Re-Vana Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Re-Vana Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelfast

Employee Range22

Year Founded2015

Last FundingNov 30, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.